<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2019.93021</article-id><article-id pub-id-type="publisher-id">HJBM-31385</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20190300000_13590704.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  狂犬病疫苗研究进展
   Research Progress on Rabies Vaccine
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>乾芬</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>华兰生物疫苗有限公司，河南 新乡</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>07</month><year>2019</year></pub-date><volume>09</volume><issue>03</issue><fpage>143</fpage><lpage>147</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   狂犬病是由狂犬病毒引起的人畜共患传染病。狂犬病毒感染温血动物和人类的中枢神经系统后导致急性致命脑脊髓炎。狂犬病疫苗的开发有着悠久的历史，19世纪后期开发出第一代狂犬病疫苗，随后开发出更高疗效和更少不良反应的第二代和第三代疫苗，疫苗的正确应用对于防止狂犬病的发展是非常有效的。大量的实验性疫苗正在发展中，包括DNA疫苗、重组病毒疫苗和重组蛋白疫苗。本文概述狂犬病接种疫苗的过去、现在和可能的未来。 Rabies is a zoonotic infection caused by rabies virus. The rabies virus infects the central nervous system of warm-blooded animals and humans leading to acute lethal encephalomyelitis. The development of rabies vaccine has a long history. The first generation of rabies vaccine was developed in the late 19th century, followed by the development of second- and third-generation vaccines with higher efficacy and less adverse reactions. The correct application of vaccines to prevent the development of rabies is very effective. A large number of experimental vaccines are under development, including DNA vaccines, recombinant viral vaccines and recombinant protein vaccines. This article outlines the past, present and possible future of rabies vaccine.
    
  
 
</p></abstract><kwd-group><kwd>狂犬病疫苗，狂犬病毒，研究,  Rabies Vaccine</kwd><kwd> Rabies Virus</kwd><kwd> Research</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>狂犬病疫苗研究进展<sup> </sup></title><p>王乾芬</p><p>华兰生物疫苗有限公司，河南 新乡</p><p><img src="//html.hanspub.org/file/6-1530131x1_hanspub.png" /></p><p>收稿日期：2019年7月2日；录用日期：2019年7月17日；发布日期：2019年7月24日</p><disp-formula id="hanspub.31385-formula37"><graphic xlink:href="//html.hanspub.org/file/6-1530131x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>狂犬病是由狂犬病毒引起的人畜共患传染病。狂犬病毒感染温血动物和人类的中枢神经系统后导致急性致命脑脊髓炎。狂犬病疫苗的开发有着悠久的历史，19世纪后期开发出第一代狂犬病疫苗，随后开发出更高疗效和更少不良反应的第二代和第三代疫苗，疫苗的正确应用对于防止狂犬病的发展是非常有效的。大量的实验性疫苗正在发展中，包括DNA疫苗、重组病毒疫苗和重组蛋白疫苗。本文概述狂犬病接种疫苗的过去、现在和可能的未来。</p><p>关键词 :狂犬病疫苗，狂犬病毒，研究</p><disp-formula id="hanspub.31385-formula38"><graphic xlink:href="//html.hanspub.org/file/6-1530131x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1530131x7_hanspub.png" /> <img src="//html.hanspub.org/file/6-1530131x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>狂犬病是一种人畜共患的疾病，感染是通过患病的动物传染给人类的。引起狂犬病的动物主要有狗、浣熊、臭鼬、蝙蝠和狐狸。狂犬病是由病毒引起的，病毒攻击神经系统后通过唾液排出。狂犬病影响大脑和脊髓(中枢神经系统)，初始症状类似流感、发烧、头痛，但是感染可以快速发展到幻觉、瘫痪，并最终死亡，目前没有有效的疗法。一旦发生疾病，死亡率近100%。狂犬病在150多个国家和地区都有存在。据世卫组织估计，每年有近55,000人死于狂犬病。狗是这背后的主要原因，其中大约99%人类死亡是狗咬伤导致的。发展中国家和亚发展中国家都是狂犬病的受害者。有了接触后预防制度，每年有327,000人可以预防这种疾病 [<xref ref-type="bibr" rid="hanspub.31385-ref1">1</xref>] 。</p><p>狂犬病是感染狂犬病毒导致的一种病毒性疾病。狂犬病病毒呈子弹状，弹状病毒科狂犬病毒属的模式种，病毒具有包膜和单反密码股的RNA基因组，基因组编码的5个基因是高度保守的，这些基因编码核蛋白(N)、磷蛋白质(P)、基质蛋白(M)、糖蛋白(G)和病毒RNA聚合酶(L)，其中G蛋白是主要的保护性抗原 [<xref ref-type="bibr" rid="hanspub.31385-ref2">2</xref>] 。</p></sec><sec id="s4"><title>2. 狂犬病疫苗的起源</title><p>狂犬病毒在自然界中广泛传播。1804年，Georg Gottfried Zinke使用唾液注入的方法第一个将狂犬病病毒从患狂犬病的狗到正常的狗，从狗到一只兔子和一只母鸡进行传播。这证明了该疾病具有传染性，但物种敏感性还不清楚，直到Victor Galtier展示了狂犬病病毒从狗到兔子再到兔子的传播。然后他用患狂犬病的唾液静脉注射接种来免疫绵羊，这并没有产生疾病，但有趣的是，它保护动物免受进一步感染的影响 [<xref ref-type="bibr" rid="hanspub.31385-ref3">3</xref>] 。</p><p>1885年7月6日，9岁的Joseph Meister从阿尔萨斯被带走，他于7月4日被染了狂犬病的狗咬伤。Grancher说服了巴斯德提供6月21日死于狂犬病的兔子脊髓中获得的乳剂(乳剂在干燥的空气中保存了15天)。在10天内，孩子得到13次深层接种，脊髓的部分逐渐更新鲜(毒力更强)，直到三个月零三天后，他宣布孩子的生命脱离危险。10月20日，他成功治疗一个六天前被疯狗感染的病人。到1886年，他治疗了来自欧洲各地、俄罗斯和美国的350例病人 [<xref ref-type="bibr" rid="hanspub.31385-ref4">4</xref>] 。</p><p>尽管有一些对于含有致命病毒疫苗安全性的抨击，但是医学界还是迅速接受了巴斯德的治疗方法。为了使患者避免疫苗中病毒引起的医源性感染，Fermi和Semple引进了在神经组织疫苗制备中的一些修改，他们靠苯酚部分或完全灭活病毒。即使这些修改仍存在疫苗接种后通过不完全灭活的病毒或疫苗中的成分与成年哺乳动物神经组织的反应引起麻痹的情况发生，表现为靠敏化髓鞘碱性蛋白质引起的变态反应性脑脊髓炎，Semple疫苗仍然是用于亚洲和非洲人类 [<xref ref-type="bibr" rid="hanspub.31385-ref5">5</xref>] 。Fuenzalida和同事引进第一个无髓磷脂的制备于新生小鼠大脑的狂犬病病毒灭活疫苗 [<xref ref-type="bibr" rid="hanspub.31385-ref6">6</xref>] ，这种疫苗仍广泛应用于南美洲。所以，狂犬病靠接种疫苗是可预防的，并且一些新的狂犬病疫苗已被成功进行了研究。</p></sec><sec id="s5"><title>3. 鸭胚胎疫苗</title><p>严重反应较少的另一个疫苗是鸭胚疫苗(duck embryo vaccine简称DEV)，该疫苗通过在受孕鸭蛋里传播的病毒制备 [<xref ref-type="bibr" rid="hanspub.31385-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref8">8</xref>] 。然而，DEV不如脑组织疫苗的免疫原性强，并不总是能预防狂犬病。瑞士血清和疫苗研究所随后通过引入纯化的DEV (PDEV)改善了DEV，PDEV含有约1%的DEV蛋白质，因此降低了过敏反应的风险 [<xref ref-type="bibr" rid="hanspub.31385-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref10">10</xref>] 。密度梯度超速离心法产生的病毒浓度大幅度增加了疫苗的有效性和其引起人类病毒中和抗体应答反应的能力。PDEV至今仍在生产，并用于全球人类的疫苗接种。</p></sec><sec id="s6"><title>4. 细胞培养疫苗</title><p>细胞培养狂犬病疫苗作为一种新的发展逐渐蔓延。第一次组织培养疫苗来自生长在仓鼠肾细胞的病毒 [<xref ref-type="bibr" rid="hanspub.31385-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref11">11</xref>] 。仓鼠肾细胞狂犬病疫苗(PHKCV)是在莫斯科开发的，现在批准在中国使用和生产。紧随其后的狂犬病毒固定株是在人类二倍体细胞株中生长 [<xref ref-type="bibr" rid="hanspub.31385-ref12">12</xref>] 。最初使用肺细胞株WI-38，但随后转用MRC-5细胞株，该细胞株促使了1970年代中期人类二倍体细胞疫苗(HDCV)的发展和许可。然后Pitman-Moore狂犬病病毒株适应了WI-38 [<xref ref-type="bibr" rid="hanspub.31385-ref13">13</xref>] ，自由病毒被β-丙内酯灭活，超速离心浓缩 [<xref ref-type="bibr" rid="hanspub.31385-ref14">14</xref>] 。人类二倍体细胞疫苗(HDCV)比在那段时间其他所有的疫苗更好地诱导了动物和人类免疫反应 [<xref ref-type="bibr" rid="hanspub.31385-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref16">16</xref>] 。接种HDCV不仅产生更高的抗体水平，而且接种疫苗后抗体出现的更早。使用这种疫苗，可能首次表明恶性病毒感染几个小时后疫苗的注射可以保护动物免于狂犬病 [<xref ref-type="bibr" rid="hanspub.31385-ref17">17</xref>] 。</p><p>自那时起，为了在较低的成本下生产像HDCV类似效价的疫苗，全球开始了一系列不同细胞培养疫苗的开发。狂犬病吸附疫苗(RVA)是由已适应二倍体猴肺成纤维细胞系的狂犬病病毒株制备的。狂犬病毒靠β-丙内酯灭活，靠吸附到磷酸铝进行浓缩 [<xref ref-type="bibr" rid="hanspub.31385-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref19">19</xref>] 。在效价和安全性方面，该疫苗被认为是等同于HDCV的 [<xref ref-type="bibr" rid="hanspub.31385-ref20">20</xref>] 。</p><p>HDCV的另一种选择是使用纯化的小鸡胚胎细胞(PCEC) [<xref ref-type="bibr" rid="hanspub.31385-ref21">21</xref>] 。PCECV是通过生长在原始的小鸡胚胎成纤维细胞的狂犬病毒毒株制备的鸡胚疫苗。病毒用β-丙内酯灭活，蔗糖梯度区域离心纯化浓缩。对比HDCV试验显示两种疫苗之间没有显著差异 [<xref ref-type="bibr" rid="hanspub.31385-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref23">23</xref>] 。现在，这些疫苗在全球范围内得到了成功应用。</p><p>一个连续的非洲绿猴肾细胞系Vero被用于生产另一个狂犬病疫苗 [<xref ref-type="bibr" rid="hanspub.31385-ref24">24</xref>] 。纯化的Vero细胞狂犬病疫苗(PVRV)是基于狂犬病毒的Pitmanman-Moore毒株，该毒株用β-丙内酯灭活，通过离心及超滤进行浓缩纯化。初始和增强接种后的抗体反应与接种HDCV之后的抗体反应可以相媲美 [<xref ref-type="bibr" rid="hanspub.31385-ref25">25</xref>] 。在欧洲和许多发展中国家，PVRV许可用于人类。</p></sec><sec id="s7"><title>5. 动物疫苗</title><p>第一个用于大规模狗接种的疫苗是Umeno和Doi基于Semple疫苗修饰获得的。相比用于人类的疫苗(认为需要完全灭活的病毒)，减毒的活病毒疫苗开发为兽用。细胞培养获得的疫苗可用于伴侣动物和家畜的非肠道接种，也被用于开发野生动物免疫的口服疫苗 [<xref ref-type="bibr" rid="hanspub.31385-ref26">26</xref>] 。狂犬病毒减毒菌株的高效价结合口服诱饵吸引了带病毒的野生动物如红狐狸，它在消除来自西欧的狂犬病是高度有效的。在东欧和土耳其，该疫苗仍在继续使用 [<xref ref-type="bibr" rid="hanspub.31385-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref28">28</xref>] 。</p><p>免疫接种像狐狸和浣熊的野生动物最简单的方法是通过口服疫苗接种。随着Street Alabama Dufferin (SAD B19)减毒狂犬病疫苗的发展，此方法变得可行。这种病毒通过仓鼠婴儿肾细胞系传播，甚至在高温下是稳定的。因为SAD B19为啮齿动物保留了残余致病性，更多的减毒毒株SAG2开始被开发，现在用于野生动物的疫苗接种 [<xref ref-type="bibr" rid="hanspub.31385-ref29">29</xref>] 。</p></sec><sec id="s8"><title>6. 未来的狂犬病疫苗</title><p>尽管当前商业狂犬病疫苗十分成功，但仍尝试着开发替代品。抗体已被证明是防止狂犬病毒扩散的关键 [<xref ref-type="bibr" rid="hanspub.31385-ref30">30</xref>] 。抗体的关键目标是病毒糖蛋白，糖蛋白是唯一在病毒粒子颗粒表面暴露的蛋白，一些中和单克隆抗体结合的抗原位点已确定在这个蛋白上 [<xref ref-type="bibr" rid="hanspub.31385-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref32">32</xref>] 克隆狂犬病毒糖蛋白到细菌质粒上，然后在系统层面上表达蛋白质，产生了大量的具有潜在新狂犬病疫苗的替代方法。在重组蛋白中，载体范围内表达已被证明在小鼠模型接种和病毒挑战方面具有保护性。尽管具有快速诱导狂犬病毒中和抗体高效价的能力，但是，能够有效地防止小动物模型感染，它们主要在成本和接受供人类使用方面无法挑战现有的疫苗。</p><p>开放操纵病毒基因组的能力是研究狂犬病毒生物学和狂犬病疫苗的新手段。减毒、狂犬病毒固定毒株SAD B19 (美国SAD毒株的欧洲衍生物)是由Conzelmann和Schnell从质粒编码基因组中恢复过来的。通过操纵狂犬病毒基因组为疫苗接种生物学的一系列发展铺平了道路。</p><p>狂犬病毒治疗领域的持续挑战是如何治愈已经超出姑息治疗的狂犬病病人。实验模型表明，哺乳动物宿主在大脑中产生对于狂犬病毒感染有力的先天免疫反应。然而，有证据表明这种反应是一定程度上被病毒磷蛋白质反抗的 [<xref ref-type="bibr" rid="hanspub.31385-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.31385-ref34">34</xref>] 。这种颠覆可能是不能通过先天的和适应性的免疫反应来控制狂犬病毒在中枢神经系统中复制的原因，这最终导致了宿主的死亡。因此鼓励预防治疗，具有修饰的狂犬病基因似乎减弱更加致命的毒株感染 [<xref ref-type="bibr" rid="hanspub.31385-ref35">35</xref>] ，它可能成为一个改善狂犬病毒感染最糟糕结果的未来可能成功的基础治疗。</p></sec><sec id="s9"><title>文章引用</title><p>王乾芬. 狂犬病疫苗研究进展 Research Progress on Rabies Vaccine[J]. 生物医学, 2019, 09(03): 143-147. https://doi.org/10.12677/HJBM.2019.93021</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31385-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2005) Expert Consultation on Rabies. Geneva.</mixed-citation></ref><ref id="hanspub.31385-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Finke, S. and Conzelmann, K.K. (2005) Replication Strat-egies of Rabies Virus. Virus Research, 111, 120-131.  
&lt;br&gt;https://doi.org/10.1016/j.virusres.2005.04.004</mixed-citation></ref><ref id="hanspub.31385-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pasteur, L., Chamberland, C. and Roux, P.P.E. (1884) Nouvelle Communication sur la rage. Comptes rendus de l’Académie des Sciences (Paris), 98, 457-463, 1229-1231.</mixed-citation></ref><ref id="hanspub.31385-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Louis Pasteur, N.J. (1962) A Master of Scientific Enquiry. The Scientific Book Guild, London.</mixed-citation></ref><ref id="hanspub.31385-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Javier, R.S., Kunishita, T., Koike, F. and Tabira, T. (1989) Semple Rabies Vaccine: Presence of Myelin Basic Protein and Proteolipid Protein and Its Activity in Experimental Allergic Encephalomyelitis. Journal of the Neurological Sciences, 93, 221-230. &lt;br&gt;https://doi.org/10.1016/0022-510X(89)90192-5</mixed-citation></ref><ref id="hanspub.31385-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Fuenzalida, E., Palacios, R. and Borgono, J.M. (1964) Anti-Rabies Antibody Response in Man to Vaccine Made from Infected Suckling-Mouse Brains. Bulletin of the World Health Organization, 30, 431-436.</mixed-citation></ref><ref id="hanspub.31385-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Peck, F.B., Powell, H.M. and Culbertson, C.G. (1956) Duck-Embryo Rabies Vaccine: Study of Fixed Virus Vaccine Grown in Embryonated Duck Eggs and Killed with Beta-Propiolactone. JAMA, 162, 1373-1376.  
&lt;br&gt;https://doi.org/10.1001/jama.1956.02970320021006</mixed-citation></ref><ref id="hanspub.31385-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gluck, R., Wegmann, A., Germanier, R., Keller, H., Hess, M.W., Kraus-Ruppert, R. and Wandeler, A.I. (1984) A New, Highly Immunogenic Duck Embryo Rabies Vaccine. The Lancet, 1, 844-845.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(84)92286-4</mixed-citation></ref><ref id="hanspub.31385-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gluck, R., Matthieu, J.M., Wegmann, A. and Mean, F. (1986) Absence of Myelin Basic Protein in an Improved Purified Duck Embryo Rabies Vaccine. Neurochemical Pathology, 4, 69-75.</mixed-citation></ref><ref id="hanspub.31385-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kissling, R.E. (1958) Growth of Rabies Virus in Non-Nervous Tissue. Proceedings of the Society for Experimental Biology and Medicine, 98, 223-225. &lt;br&gt;https://doi.org/10.3181/00379727-98-23997</mixed-citation></ref><ref id="hanspub.31385-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kissling, R.E. and Reese, D.R. (1963) Anti-Rabies Vaccine of Tissue Culture Origin. The Journal of Immunology, 91, 362-368.</mixed-citation></ref><ref id="hanspub.31385-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wiktor, T.J., Fernandes, M.V. and Koprowski, H. (1964) Cultivation of Rabies Virus in Human Diploid Cell Strain WI-38. The Journal of Immunology, 93, 353-366.</mixed-citation></ref><ref id="hanspub.31385-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wiktor, T.J., Plotkin, S.A. and Koprowski, H. (1978) Development and Clinical Trials of the New Human Rabies Vaccine of Tissue Culture (Human Diploid Cell) Origin. Developments in Biological Standardization, 40, 3-9.</mixed-citation></ref><ref id="hanspub.31385-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Plotkin, S.A. (1980) Rabies Vaccine Prepared in Human Cell Cultures: Progress and Perspectives. Reviews of Infectious Diseases, 2, 433-448. &lt;br&gt;https://doi.org/10.1093/clinids/2.3.433</mixed-citation></ref><ref id="hanspub.31385-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wiktor, T.J., Sokol, F., Kuwert, E. and Koprowski, H. (1969) Immunogenicity of Concentrated and Purified Rabies Vaccine of Tissue Culture Origin. Experimental Biology and Medicine, 131, 799-805.  
&lt;br&gt;https://doi.org/10.3181/00379727-131-33981</mixed-citation></ref><ref id="hanspub.31385-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wiktor, T.J., Plotkin, S.A. and Grella, D.W. (1973) Human Cell Culture Rabies Vaccine. Antibody Response in Man. JAMA, 224, 1170-1171. &lt;br&gt;https://doi.org/10.1001/jama.1973.03220220072012</mixed-citation></ref><ref id="hanspub.31385-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sikes, R.K., Cleary, W.F., Koprowski, H., Wiktor, T.J. and Kaplan, M.M. (1971) Effective Protection of Monkeys against Death from Street Virus by Post-Exposure Admin-istration of Tissue-Culture Rabies Vaccine. Bulletin of the World Health Organization, 45, 1-11.</mixed-citation></ref><ref id="hanspub.31385-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Berlin, B.S., Mitchell, J.R., Burgoyne, G.H., Brown, W.E. and Goswick, C. (1983) Rhesus Diploid Rabies Vaccine (Adsorbed), a New Rabies Vaccine. II. Results of Clinical Studies Simulating Prophylactic Therapy for Rabies Exposure. JAMA, 249, 2663-2665. &lt;br&gt;https://doi.org/10.1001/jama.1983.03330430039026</mixed-citation></ref><ref id="hanspub.31385-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Burgoyne, G.H., Kajiya, K.D., Brown, D.W. and Mitchell, J.R. (1985) Rhesus Diploid Rabies Vaccine (Adsorbed): A New Rabies Vaccine. Using FRhL-2 Cells. The Journal of Infectious Diseases, 152, 204-210.  
&lt;br&gt;https://doi.org/10.1093/infdis/152.1.204</mixed-citation></ref><ref id="hanspub.31385-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Berlin, B.S. (1990) Rabies Vaccine Adsorbed: Neutralizing Antibody Titers after Three-Dose Pre-Exposure Vaccination. American Journal of Public Health, 80, 476-477. &lt;br&gt;https://doi.org/10.2105/AJPH.80.4.476</mixed-citation></ref><ref id="hanspub.31385-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kondo, A. (1965) Growth Characteristics of Rabies Virus in Primary Chicken Embryo Cells. Virology, 27, 199-204.  
&lt;br&gt;https://doi.org/10.1016/0042-6822(65)90160-1</mixed-citation></ref><ref id="hanspub.31385-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Nicholson, K.G., Farrow, P.R., Bijok, U. and Barth, R. (1987) Pre-Exposure Studies with Purified Chick Embryo Cell Culture Rabies Vaccine and Human Diploid Cell Vaccine: Se-rological and Clinical Responses in Man. Vaccine, 5, 208-210. &lt;br&gt;https://doi.org/10.1016/0264-410X(87)90102-2</mixed-citation></ref><ref id="hanspub.31385-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Dreesen, D.W., Fishbein, D.B., Kemp, D.T. and Brown, J. (1989) Two-Year Comparative Trial on the Immunogenicity and Adverse Effects of Purified Chick Embryo Cell Rabies Vaccine for Pre-Exposure Immunization. Vaccine, 7, 397-400. &lt;br&gt;https://doi.org/10.1016/0264-410X(89)90152-7</mixed-citation></ref><ref id="hanspub.31385-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Montagnon, B.J. (1989) Polio and Rabies Vaccines Produced in Continuous Cell Lines: A Reality for Vero Cell Line. Developments in Biological Standardization, 70, 27-47.</mixed-citation></ref><ref id="hanspub.31385-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ajjan, N. and Pilet, C. (1989) Comparative Study of the Safety and Protective Value, in Pre-Exposure Use, of Rabies Vaccine Cultivated on Human Diploid Cells (HDCV) and of the New Vaccine Grown on Vero Cells. Vaccine, 7, 125-128. &lt;br&gt;https://doi.org/10.1016/0264-410X(89)90050-9</mixed-citation></ref><ref id="hanspub.31385-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Gueu, L., Schares, S., Schinck, C., et al. (2008) Genetic Characterization of Attenuated SAD Rabies Virus Strains Used for Oral Vaccination of Wildlife. Vaccine, 26, 3227-3235. &lt;br&gt;https://doi.org/10.1016/j.vaccine.2008.04.007</mixed-citation></ref><ref id="hanspub.31385-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Cliquet, F. and Aubert, M. (2004) Elimination of Terrestrial Rabies in Western European Countries. Developmental Biology, 119, 185-204.</mixed-citation></ref><ref id="hanspub.31385-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Vos, A., Freuling, C., Eskiizmirliler, S., et al. (2009) Rabies in Foxes, Aegean Region, Turkey. Emerging Infectious Diseases, 15, 1620-1622. &lt;br&gt;https://doi.org/10.3201/eid1510.090203</mixed-citation></ref><ref id="hanspub.31385-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lafay, F., Benejean, J., Tuffereau, C., et al. (1994) Vaccination against Rabies: Construction and Characterization of SAG2, a Double Avirulent Derivative of SADBern. Vaccine, 12, 317-320.  
&lt;br&gt;https://doi.org/10.1016/0264-410X(94)90095-7</mixed-citation></ref><ref id="hanspub.31385-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Hooper, D.C., Morimoto, K., Bettle, M., et al. (1998) Col-laboration of Antibody and Inflammation in Clearance of Rabies Virus from the Central Nervous System. Journal of Virology, 72, 3711-3719.</mixed-citation></ref><ref id="hanspub.31385-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Seif, I., Coulon, P., Rollin, P.E., et al. (1985) Rabies Virulence: Effect on Pathogenicity and Sequence Characterisation of Rabies Virus Mutations Affecting Antigenic Site III of the Glycoprotein. Journal of Virology, 53, 926-934.</mixed-citation></ref><ref id="hanspub.31385-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Prehaud, C., Coulon, P., Lafay, F., et al. (1988) Antigenic Site II of Rabies Virus Glyco-protein: Structure and Role in Viral Virulence. Journal of Virology, 62, 1-7.</mixed-citation></ref><ref id="hanspub.31385-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Vidy, A., Chelbi-Alix, M. and Blondel, D. (2005) Rabies Virus P Protein Interacts with STAT 1 and Inhibits Interferon Signal Transduction. Journal of Virology, 79, 14411-14420. &lt;br&gt;https://doi.org/10.1128/JVI.79.22.14411-14420.2005</mixed-citation></ref><ref id="hanspub.31385-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Brzozka, K., Finke, S. and Conzelmann, K.K. (2006) Inhibition of Interferon Signalling by Rabies Virus Phosphoprotein P: Activation-Dependent Binding of STAT1 and STAT2. Journal of Virology, 80, 2675-2683.  
&lt;br&gt;https://doi.org/10.1128/JVI.80.6.2675-2683.2006</mixed-citation></ref><ref id="hanspub.31385-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Wen, Y., Wang, H., Wu, H., et al. (2011) Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination. Journal of Virology, 85, 1634-1644.  
&lt;br&gt;https://doi.org/10.1128/JVI.01552-10</mixed-citation></ref></ref-list></back></article>